US 2024/0180888 A1Published application

C5ar1 inhibitors for treating hypersensitivity reactions to taxanes

AssigneeDompé Farmaceutici S.P.A.

InventorsMarcello ALLEGRETTI, Andrea ARAMINI, Piergiorgio AMENDOLA, Laura BRANDOLINI, Maria Candida CESTA, Anna SIRICO

Life of this patent

Estimating the term…

Abstract

The present invention relates to the use of a C5aR1 inhibitor for the prevention or treatment of a hypersensitivity reaction (HSR) to a taxane in an individual.

Claims13

Dependent claims

A method for the prevention or treatment of a hypersensitivity reaction (HSR) to a taxane in an individual, the method comprising administering a C5aR1 inhibitor to the individual.

Dependencies are inferred from the claim text.

Facts

Application: 18/282,357Filed 17 Mar 2022
Priority: EP 21163292.217 Mar 2021
Published: 6 Jun 2024
Term ends: Not estimatedThe source records don’t support an estimate.

Classification12 codes

A61K 31/405
Indoles, e.g. pindolol: indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
A61K 31/451
Non condensed piperidines, e.g. piperocaine: having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine,…
A61K 31/00
Medicinal preparations containing organic active ingredients
A61K 31/427
Thiazoles: not condensed and containing further heterocyclic rings

Family

No related US applications are recorded in the indexed filing history.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results